Dinutuximab Beta in Children with High-Risk Neuroblastoma: Experience from a Single Center in Croatia

To determine the potential benefits and feasibility of administering maintenance therapy with dinutuximab beta for high-risk neuroblastoma (HRNB) in clinical practice, a retrospective review of charts of patients with HRNB treated at a single center in Croatia (2012–2021) was undertaken. Of 23 patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Giljević, Jasminka Stepan, Rajačić, Nada, Mikulić, Danko, Batoš, Ana Tripalo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318789/
https://www.ncbi.nlm.nih.gov/pubmed/35883927
http://dx.doi.org/10.3390/children9070943

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318789/
https://www.ncbi.nlm.nih.gov/pubmed/35883927
http://dx.doi.org/10.3390/children9070943

Ejemplares similares